This may be due to the fact that in the TME, pDCs frequently acquire a tolerogenic phenotype, which is associated with the presence of immunosuppressive cytokines (e.g., TGF-β, IL-10), tumor metabolites, and interactions with inhibitory receptors (e.g., blood dendritic cell antigen 2—BDCA-2, immunoglobulin-like transcript 7—ILT7). Here, LILRA4 is linked to neoplasm.